# Paxman > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/paxman). ## Overview Paxman AB develops and commercializes scalp cooling systems used to reduce chemotherapy-induced hair loss. The group is headquartered in Sweden and operates through subsidiaries in the UK, the US, Canada and other markets, serving hospitals and oncology clinics worldwide. ## Products & services • Scalp cooling systems for chemotherapy patients • Cooling caps and related consumables • Rental and sale-based system installations • Clinical training, support and service • R&D for neuropathy-prevention and next-gen devices - **Scalp cooling systems** (65%) — Medical devices used during chemotherapy to reduce hair loss. - **Consumables and accessories** (15%) — Caps, connectors and related items used with installed systems. - **System rentals and placements** (10%) — Installed-base revenue from rental and placement agreements. - **Service and training** (5%) — Customer support, onboarding and clinical training for users. - **R&D and emerging products** (5%) — Development of next-generation cooling and neuropathy devices. - Scalp cooling systems for chemotherapy patients - Cooling caps and related consumables - Rental and sale-based system installations - Clinical training, support and service - R&D for neuropathy-prevention and next-gen devices ## Customers Paxman sells primarily to hospitals, oncology centers and community cancer clinics that administer chemotherapy and need a scalp cooling solution for patients. In some markets, systems are placed through rental or signed delivery agreements, while in others they are sold outright to the customer. The end user is the patient, but the purchasing decision is typically made by clinical, operational and reimbursement stakeholders within the treatment center. - **Hospital oncology departments** (primary) — Buy installed scalp cooling systems to offer supportive care during chemotherapy. - **Community oncology clinics** (primary) — Adopt the system to improve patient experience and broaden service offerings. - **North American rental customers** (primary) — Use signed delivery and rental agreements for installed systems and recurring use. - **International distributors and clinics** (secondary) — Purchase systems for sale or deployment in markets outside North America. - **Patients and patient advocacy channels** (secondary) — Influence adoption by creating demand for hair-loss mitigation during treatment. - Hospitals and cancer centers buying scalp cooling for chemotherapy patients - Community oncology clinics seeking patient-retention and service differentiation - Clinics using rental or placement models in North America - Healthcare providers that need training, installation and ongoing support - Patients are the end users, but providers make the purchase decision ## Geography Paxman is based in Sweden, with production and sales carried out through its UK subsidiary and operating entities in the US and Canada. Reported installed systems span Europe, Asia, North America, the UK, South America and Oceania, showing a broad international footprint. North America is especially important because the company uses rental and delivery agreements there, while other regions are more often served through direct sales. - **Europe** (35%) - **Asia** (20%) - **North America** (25%) - **South America** (10%) - **Oceania** (10%) - Headquartered in Karlshamn, Sweden - Production and sales run through the UK subsidiary - Operating entities in the US, Canada, Sweden and Italy - Installed systems across Europe, Asia, North America and Oceania - North America uses rental and delivery agreements for installed systems ## Strategy Paxman is building out a broader oncology side-effect management platform around its scalp cooling franchise. Its priorities include clinical evidence generation, reimbursement expansion in the US, and commercialization of next-generation products such as a neuropathy-prevention device and a new cooling cap. The company is also integrating acquired operations into a unified structure to support scale and cross-selling. - **US reimbursement expansion** (short-term) — Coverage and payment drive utilization, adoption and recurring revenue in the largest market. - **Clinical evidence generation** (medium-term) — Trials and studies strengthen physician confidence and payer support for broader use. - **Product diversification** (medium-term) — New devices reduce dependence on a single product category and widen the addressable market. - **Operating integration** (short-term) — A unified structure can improve execution, customer service and scalability. - Expand reimbursement and coverage in the US - Use clinical data to support adoption and payer acceptance - Commercialize a neuropathy-prevention device - Launch next-generation cooling caps and related products - Integrate acquired operations into a single operating model ## Risks Paxman depends on adoption by healthcare providers and on reimbursement decisions, especially in the US where payment coverage can materially affect utilization. The business also faces execution risk from integrating acquired operations, scaling manufacturing and bringing new products through clinical and regulatory pathways. As a medical device company, it is exposed to clinical evidence risk, regulatory approval risk and competition from alternative supportive-care solutions. - **Reimbursement dependence in the US** [high] — Coverage and payment determine whether clinics can justify adoption and patients can access treatment. - **Integration risk after acquisition** [high] — Combining systems, teams and processes can create temporary disruption and execution complexity. - **Clinical and regulatory risk** [medium] — New products need supportive data and approvals before broad commercialization. - **Competitive pressure** [medium] — Alternative scalp cooling providers and other supportive-care options can limit pricing and share gains. - US reimbursement changes can affect utilization and customer adoption - Integration of acquired operations can disrupt execution and service quality - Clinical trial outcomes may delay or weaken product commercialization - Regulatory approvals are required for new devices and indications - Competition in scalp cooling can pressure installed-base growth ## Accounting Paxman’s reporting is affected by revenue timing across rental, placement and direct-sale arrangements, which can differ by geography and contract type. The acquisition of Dignitana introduces purchase accounting judgments, including preliminary purchase price allocation and the valuation of acquired intangibles. Investors should also watch capitalization and amortization of development-related assets, as well as any impairment risk tied to acquired or internally developed intangible assets. - **Revenue recognition by contract type** — Affects quarterly comparability and installed-base revenue timing - **Purchase price allocation** — Can materially affect amortization and reported earnings - **Intangible asset amortization and impairment** — Influences operating profit and balance sheet carrying values - **Development cost accounting** — Affects EBITDA, profit and asset base - Revenue recognition differs between rentals, placements and outright sales - North American agreements can create timing differences in reported revenue - Acquisition accounting requires valuation of acquired intangibles - Development projects may involve capitalization and later amortization - Acquired goodwill and intangibles may face impairment testing --- *Last updated: 2026-08-11T04:04:55.215165+00:00*